drugset / Trial / NCT06220123

A Study to Evaluate the Efficacy and Safety of SHR-2004 Injection in Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery

NCT06220123

Phase 2 Completed 225 enrolled Beijing Suncadia Pharmaceuticals Co., Ltd
RandomizedParallel-groupOpen-labelPrevention

Summary

This study is designed to evaluate the efficacy and safety of SHR-2004 injection in preventing postoperative venous thromboembolism in patients undergoing ovarian cancer surgery.

Timeline

Start
2024-02-16
Primary completion
2024-12-31
Completion
2024-12-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Enoxaparin sodium Other / unclassified
Comparator Rivaroxaban Other / unclassified
Subject SHR-2004 Monoclonal antibody

Indications

No indication recorded.